Hsp90 or Heat Shock Protein 90, is a chaperone protein that plays a significant role in cellular processes like apoptosis, protein folding/unfolding and degradation, cell cycle control, cell survival, hormones, and other signaling pathways. Hsp90 has become a protein of interest for researchers over the last many years as it is involved in regulating the cell cycle. Targeting these proteins could be a potential approach for the treatment of various diseases like cancer, HIV, AIDS, and protozoal diseases. Therefore, a number of Hsp 90 inhibitors are undergoing clinical trials for a variety of diseases like Non-Small Cell Lung Cancer, solid tumors, Psoriasis Vulgaris, Hidradenitis Suppurativa, and breast cancer. These are being tried for various diseases in combination therapy with chemotherapy and/or radiation therapy. The development and launch of newer products by the market players will significantly enhance the revenue of the Hsp90 Inhibitors market over the forecast years. For instance, Non-Small Cell Lung Cancer accounts for 81% of all lung cancers in the USA, and according to the American Cancer Society, it is estimated that 238,340 people will be diagnosed with lung cancers in the USA in 2023. Also, according to the European Federation of Pharmaceutical Industries and Associations, in 2018, Hungary had the highest incidence of lung cancer, with 113.6 cases per 100,000 people, followed by Greece and Denmark.
A number of these inhibitors are in the market, while many are in ongoing clinical trials. 27 companies have various products in their pipelines, with 21 products in various stages of clinical trials. 3 products are in Phase 3, 8 products are in Phase 2, and 10 products are in Phase 1 of the clinical trials.
Drugs in Pipeline
- Ganetespib (ADX-1612)
- Tanespimycin (BMS-722782)
- Luminespib (AUY922)
- Onalespib (AT13387)
- SNX-5422
- Retaspimycin (IPI-504)
- Icapamespib (PU-AD)
- RGRN-305
- Zelavespib Intravenous (PU-H71 IV)
- Jeselhy (Pimitespib)
- XL888
- IPI 493
- JIN-001
- KW 2478
- RTA 901
- Locnartecan (PEN-866)
- DS-2248
- LAM 003
- TQB3474
- Gamitrinib
- Zelavespib Oral (PU-H71 Oral)
Clinical Activity and Developments of Hsp90 Inhibitors
Companies have their products in the pipeline in various phases of clinical trials, with approximately 21 products for 130 diseases.
- In October 2018, Jonsson Comprehensive Cancer Center completed a Phase 1 clinical study to evaluate the safety and tolerability of Pemetrexed disodium and Hsp90 inhibitor AUY922 in treating patients with previously treated stage IV Non-Small Cell Lung Cancer.
- In August 2022, Aarhus University Hospital completed a Phase 1 clinical study to evaluate the efficacy and safety of a novel Hsp90 inhibitor RGRN-305 in the treatment of moderate to severe Hidradenitis Suppurativa.
|
Molecule name |
Number of studies |
|
Ganetespib (ADX-1612) |
41 |
|
Tanespimycin (BMS-722782) |
35 |
|
Retaspimycin (IPI-504) |
13 |
|
Luminespib (AUY922) |
30 |
|
Onalespib (AT 13387) |
14 |
Target Indication Analysis of Hsp90 Inhibitors
The HSP90 protein family's members are highly conserved, all-around entities that have a molecular weight of roughly 90 kDa. They are molecular chaperones that aid in correctly folding newly generated or improperly folded proteins to prevent aggregation. With the exception of archaea, they are found in all living things and makeup between 1% and 2% of all the proteins in mammalian cells when there is no stress. Apoptosis, cell cycle regulation, cell viability, protein folding and degradation, and signalling events are just a few of the critical cellular processes and regulatory pathways in which HSP90 proteins participate. Additionally, they trigger adaptive immunity by stimulating dendritic cells and antigen-presenting cells. There have been trials for indications like Advanced Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors, Peripheral Arterial Diseases, Sarcoma, Connective and soft tissue neoplasms, Urogenital neoplasms, Prostatic neoplasms, Stomach and Esophageal Neoplasms, cancers, HIV-AIDS and some protozoal diseases. and others. Clinical trials are being conducted with various Hsp90 Inhibitors candidates globally.
Hsp90 Inhibitors Regional Analysis
Hsp90 Inhibitors Market
Many studies are being conducted globally for the development and trials of Hsp90 inhibitors individually as well as in combination with other drugs. USA, Japan, South Korea and other European countries are the regions that are working on developing novel Hsp90 inhibitors. Developed countries like Europe and USA have favourable policies that are helpful for new drug development. USA has many reimbursement policies that makes a ground for the new drug launches and maximize their sales. According to a report, USA had an R&D expenditure of US $102.3 billion in 2021 which has been continuously increasing providing a solid ground for the scientific discovery of new molecules.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
Currently, there is no FDA-approved drug in the Hsp90 inhibitors category.
These are being used in various indications like Advanced Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors, Peripheral Arterial Diseases, Stomach and Esophageal Neoplasms, cancers, HIV-AIDS, and some protozoal diseases
Aldeyra Therapeutics, Inc., BMS, Ligand Pharmaceuticals Incorporated, Otsuka Pharmaceutical Co., Ltd., and Esanex are some of the major market players for Hsp90 inhibitors.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to cancer and HIV AIDS are the key opportunities for Hsp90 Inhibitors in the market.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Ganetespib (ADX-1612)
- Tanespimycin (BMS-722782)
- Luminespib (AUY922)
- Onalespib (AT13387)
- SNX-5422
- Retaspimycin (IPI-504)
- Icapamespib (PU-AD)
- RGRN-305
- Zelavespib Intravenous (PU-H71 IV)
- Jeselhy (Pimitespib)
- XL888
- IPI 493
- JIN-001
- KW 2478
- RTA 901
- Locnartecan (PEN-866)
- DS-2248
- LAM 003
- TQB3474
- Gamitrinib
- Zelavespib Oral (PU-H71 Oral)